Fig. 3

Expression of KMT2D aggravates malignant behaviors of OSCC cells. A Immunoblotting of KMT2D in SCC4, SCC25, and CAL27 cells respectively transfected with Sh-CON and Sh-KMT2D. B Colony formation assays and quantification analysis generated from SCC4 and SCC25 cells transfected with Sh-CON and Sh-KMT2D. C Sphere formation assays and quantification analysis carried out from SCC4, SCC25, and CAL27 cells transfected with Sh-CON and Sh-KMT2D. (scale bars = 50 μm). D Wound healing assays and quantification analysis generated from SCC4, SCC25, and CAL27 cells transfected with Sh-CON and Sh-KMT2D. (scale bars = 50 μm). E Invasion assays and quantification analysis generated from SCC4, SCC25 cells transfected with Sh-CON and Sh-KMT2D. (scale bars = 50 μm). Results are representative of at least three independent experiments (*p < 0.05, **p < 0.01 and ***p < 0.001). Data are presented as means ± SD; SD standard deviation